APA (7th ed.) Citation

Wang XJ, Wang YH, Ong MJC, Gkitzia C, Soh SY, & Hwang WYK. (2022). Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective. Dove Medical Press.

Chicago Style (17th ed.) Citation

Wang XJ, Wang YH, Ong MJC, Gkitzia C, Soh SY, and Hwang WYK. Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective. Dove Medical Press, 2022.

MLA (9th ed.) Citation

Wang XJ, et al. Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective. Dove Medical Press, 2022.